187 related articles for article (PubMed ID: 32581161)
21. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
22. Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.
Mohassel P; Rosen P; Casciola-Rosen L; Pak K; Mammen AL
Arthritis Rheumatol; 2015 Jan; 67(1):266-72. PubMed ID: 25186009
[TBL] [Abstract][Full Text] [Related]
23. Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.
Konishi R; Ichimura Y; Tanaka R; Miyahara H; Okune M; Miyamoto M; Hara M; Iwabuchi A; Takada H; Nakagishi Y; Mizuta M; Kaneko S; Shimizu M; Morio T; Nishino I; Nomura T; Okiyama N
Immunol Med; 2024 Jun; 47(2):100-105. PubMed ID: 38174692
[TBL] [Abstract][Full Text] [Related]
24. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
25. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study.
Cordel N; Dechelotte B; Jouen F; Lamb JA; Chinoy H; New P; Vencovsky J; Mann H; Galindo-Feria AS; Dani L; Selva-O'Callaghan A; Werth VP; Ravishankar A; Landon-Cardinal O; Tressières B; Boyer O
Rheumatology (Oxford); 2023 Apr; 62(4):1711-1715. PubMed ID: 36250907
[TBL] [Abstract][Full Text] [Related]
26. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
27. Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report.
Xie JJ; Li B; Xu R; Du XZ; He JZ
BMC Pulm Med; 2021 Jun; 21(1):204. PubMed ID: 34193090
[TBL] [Abstract][Full Text] [Related]
28. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
29. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
[TBL] [Abstract][Full Text] [Related]
30. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
Kubeček O; Soukup T; Paulík A; Kopecký J
BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
32. NanoString technology distinguishes anti-TIF-1γ
Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
[TBL] [Abstract][Full Text] [Related]
33. Triple carcinomas detected in two patients with anti-transcription intermediary factor 1γ (TIF1γ) antibody-positive dermatomyositis.
Shimono M; Koike Y; Satomi N; Morisaki H; Ashida M; Murota H
Eur J Dermatol; 2022 Apr; 32(2):285-287. PubMed ID: 35866906
[No Abstract] [Full Text] [Related]
34. Association of the serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis.
Li X; Bai J; Li S; Li M; Zeng X; Wang Q; Hu C
Clin Exp Rheumatol; 2023 Mar; 41(2):230-237. PubMed ID: 36226625
[TBL] [Abstract][Full Text] [Related]
35. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
36. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
37. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.
Asano R; Shinoda K; Tsuda R; Hounoki H; Kawataka M; Makino T; Imura J; Hamaguchi Y; Tobe K
Rheumatology (Oxford); 2021 Jun; 60(6):e197-e199. PubMed ID: 33367923
[No Abstract] [Full Text] [Related]
38. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
39. A unique case of dermatomyositis associated with anti-TIF1γ antibody and chondrosarcoma.
Dziwis J; Agnihothri R; Lieberman A; Richardson CT
JAAD Case Rep; 2019 Sep; 5(9):828-830. PubMed ID: 31517008
[No Abstract] [Full Text] [Related]
40. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]